Monkeypox is DéJà Vu All Over Again

Monkeypox, is really just Moneypox

Note: actually, Monkeypox and Smallpox are indistinguishable in the lab. Monkeypox was just a clever renaming of Smallpox by Larry Brilliant, MD — a renaming job that benefits the World Health Organization (WHO) and Big Pharma ‘s propaganda narrative that attempts to herd the sheeple into taking additional dangerous and unnecessary so-called “vaccines.” This is the link to the referenced paper: “The Real Cost of Medical Decision-Making in a Commercialized, Politicized Health Care System.”

Don’t Fall for This Ruse; “We the People” need to turn up the heat and achieve the Great Flushing of any more such Globalist “Great Reset” steps

Those acquainted with the New York Yankees storied history in Major League Baseball will be familiar with Yogi Berra, a colorful catcher for the Yankees and a fountain of now-quite-famous “Yogi-isms“.

  • “Baseball is 90 percent mental. The other half is physical.”
  • “He hits from both sides of the plate. He’s amphibious.”
  • “When you come to a fork in the road, take it.”
  • “It’s déjà vu all over again.”

That last “Yogi-ism” applies to the World Health Organization (WHO) and other member of its international crimes-against-humanity syndicate . . . “It’s déjà vu all over again.”

Bioweapon #1 (Covid-19) worked so well . . . now Gates, Fauci, the WHO and their minions are releasing Bioweapon #2 (Monkeypox) — using the same playbook.

Don’t Fall for those Same, Old, Tired Tricks a Second Time . . .

Yes, we are seeing another “Event 201”-styled Staged Pandemic-Response Exercise (funded by the same people) — Complete with Simulated Newscasts

This shows the NEXT SCHEDULED Pandemic — Emergencies that will NOT END Until Our Freedoms Are Eroded and Universal Surveillance is Established


Nov 2021 Nuclear Threat Initiative (NTI) Review of March 2021 “tabletop exercise” re: a fictional outbreak of Monkeypox Moneypox — “We the People” need to turn up the heat and achieve the Great Flushing of any more such Globalist “Great Reset” steps

Read the Dec 8, 2021 Testimony from NTI’s Jaime Yassif at the U.S. House Hearing on “Biosecurity for the Future: Strengthening Deterrence and Detection”

Report Shows Gates Foundation, WHO, and ‘Big-Pharma’ Execs Took Part in Monkeypox Pandemic ‘Simulation’

Adapted from an article by Michael Nevradakis, Ph.D. , May 23, 2022 | Original The Defender article here.

The World Health Organization on Friday held an emergency meeting to discuss the outbreak of monkeypox after just 100 cases were reported across 12 countries, as a report surfaced showing the Gates Foundation, WHO and Pharma execs in March 2021 conducted a monkeypox pandemic “simulation.”

The World Health Organization (WHO) on Friday held an emergency meeting to discuss the outbreak of monkeypox after just 100 cases were reported across 12 countries. Days before the WHO convened, the Biden administration placed a $119 million order for monkeypox vaccines after the Centers for Disease Control and Prevention (CDC) confirmed six people in the U.S. were being monitored for the viral infection, and one person had tested positive.

Here we go, again . . . identified cases only . . . are the tests accurate?

  • Belgium on Sunday became the first country to introduce a compulsory 21-day quarantine for monkeypox patients after reporting four cases of the disease in the last week, Politico reported.

  • The 100 newly reported cases, or suspected cases, garnered attention because many of them do not appear to be linked to travel to Africa, where in some regions, monkeypox is endemic.

  • Cases were reported in Australia, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Israel, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland and the U.K. No deaths are reported as of yet.

  • So what? Other public health professionals said there is a low risk to the public and a low likelihood that the epidemic will last long. Any actual evidence of an emergency?

  • Monkeypox is just “renamed” small pox as you can read in this paper.

Questions are popping up about the similarity between a March 2021 tabletop “simulation” of a monkeypox outbreak and a similar simulation in 2019 — Event 201 — which amazingly (cough, cough) “predicted” the COVID-19 pandemic

Monkeypox — What is it?

Monkeypox was first discovered in 1958 in monkeys, although they are not the source of the virus. It was first identified in humans in 1970. The virus is particularly prevalent in Central and West Africa and is considered a rare zoonotic disease, which means that it is caused by germs that spread between animals and people.

Monkeypox typically is spread by wild animals, such as in instances when a human is bitten or comes into contact with animal blood or bodily fluids. However, human-to-human transmission, while rare, is possible.

The virus is known to enter the human body through broken skin, the respiratory tract, or the eyes, nose or mouth, for instance through large respiratory droplets or through contact — including sexual contact — with bodily fluids or lesions, or indirectly through contaminated clothing or linens. “Common household disinfectants can kill it.”

Symptoms of monkeypox infection tend to be mild, and include fever, rash and swollen lymph nodes, and occasionally intense headache, back pain, muscle aches, lack of energy and skin eruptions which can cause painful lesions, scabs or crusts.

There are two strains of monkeypox: a milder West African and a stronger Central African strains. The cases identified in the recent outbreak all appear to have been caused by the milder West African strain.

Did the March 2021 ‘pandemic exercise’ “predict” (cough, cough) a monkeypox outbreak? If so, then Klaus Schwab and the WEF have a bridge to sell you . . .

In October 2019, just weeks before the outbreak of COVID-19, the Johns Hopkins Center for Health Security, along with the World Economic Forum (WEF) and the Bill & Melinda Gates Foundation, organized “Event 201,” a “high-level pandemic exercise” that mirrored what later followed with COVID-19 pandemic.

In March 2021, the Nuclear Threat Initiative (NTI), in conjunction with the Munich Security Conference, held a “tabletop exercise on reducing high-consequence biological threats.” This “fictional exercise scenario” involved the simulation of “a deadly, global pandemic involving an unusual strain of monkeypox virus that first emerged in the fictional nation of Brinia and spread globally over 18 months.”

According to NTI, this exercise, which was “[d]eveloped in consultation with technical and policy experts,” brought together “19 senior leaders and experts from across Africa, the Americas, Asia, and Europe with decades of combined experience in public health, biotechnology industry, international security, and philanthropy.”Not a single elected representative of the people participated — only hand-picked so-called experts.

The exercise culminated in a report, published November 2021, titled “Strengthening Global Systems to Prevent and Respond to High-Consequence Biological Threats: Results from the 2021 Tabletop Exercise Conducted in Partnership with the Munich Security Conference.” This report contains key findings from the exercise, an recommends “actionable recommendations for the international community.”, which, of course, includes more centralized control.

The outcome of this “exercise scenario” reported a fictional pandemic which mirrors quite closely the actual events documented for Covid-19:, “a bioweapon released by terrorists, using a pathogen engineered in a laboratory with inadequate biosafety and biosecurity provisions and weak oversight.” Nations have yet to prosecute the Covid-19 terroists, but the cases have been filed.

The fictional start date of the monkeypox pandemic in this exercise was May 15, 2022. The first European case of monkeypox was identified on May 7, 2022. Wow. What a coincidence . . . Now about that bridge . . .

Key findings from the report included:

  • More surveillance, of course: a “need” for “a more robust, transparent detection, evaluation, and early warning system that can rapidly communicate actionable information about pandemic risks.”
  • More requirements, of course: “gaps in national-level preparedness,” which will require national governments to “improve preparedness by developing national-level pandemic response plans built upon a coherent system of ‘triggers’ that prompt anticipatory action, despite uncertainty and near-term costs,” described as a “no-regrets” policymaking basis.
  • More binding laws, of course: “Gaps in biological research governance” in order to “meet today’s security requirements” and be “ready for significantly expanded challenges in the future.”
  • More money, of course: “Insufficient financing of international preparedness for pandemics,” and a lack of financing for countries to “make the essential national investments in pandemic preparedness.”

So, in short, a thin story to justify an attempted power grab. Don’t fall for this ruse.

Key recommendations from the report include:

  • More data sharing, of course: Bolstering international systems “for pandemic risk assessment, warning, and investigating outbreak origins,” calling upon the WHO to “establish a graded, transparent, international public health alert system” and the United Nations system to “establish a new mechanism for investigating high-consequence biological events of unknown origin.”
  • Triggers defined/controlled by whom? The development and implementation of “national-level triggers for early, proactive pandemic response,” including the adaptation of the “no-regrets” approach to responding to pandemics via “anticipatory action” based on “triggers” that would automatically generate a response to “high-consequence biological events.”
  • Germ team hit squads to enforce quarantines without due process? The establishment of “an international entity dedicated to reducing emerging biological risks associated with rapid technology advances,” that would “support interventions throughout the bioscience and biotechnology research and development life cycle — from funding, through execution, and on to publication or commercialization.”
  • More money, of course: The development of “a catalytic global health security fund to accelerate pandemic preparedness capacity building in countries around the world,” which would include “[n]ational leaders, development banks, philanthropic donors, and the private sector” with the aim of establishing and funding “a new financing mechanism to bolster global health security and pandemic preparedness” and that would incentivize “national governments to invest in their own preparedness over the long term.”
  • Anyone representing the people’s interests? Of course not. The establishment of “a robust international process to tackle the challenge of supply chain resilience,” based on a “high-level panel’ that would be convened by the UN secretary-general “to develop recommendations for critical measures to bolster global supply chain resilience for medical and public health supplies.”

As stated in the report:

“In national pandemic response plans, specific readiness measures would be ‘triggered’ based on factors related to the potential severity of the outbreak, expected delays in situational awareness, and the time it would take to implement response measures and see results.”

The Same Covid-19 Playbook for Monkeypox which is not airborne? Why?

What would be “triggered” bears a remarkable similarity to the COVID-19-related measures of the past two-plus years.The report states:

“Although triggered actions would vary depending upon the particular needs of the country, in most cases the goals are the same: slow the spread of disease to buy time and flatten the epidemiological curve, while using that time to scale up public health and medical systems to keep up with growing caseloads and save lives.

NPIs [non-pharmaceutical interventions] such as mask mandates and ceasing mass gatherings were deemed to be critical for blocking chains of disease transmission.

Participants generally did not endorse travel restrictions such as border closures, but travel health screening measures [i.e., vaccine passports] were viewed as valuable.”

According to the results of the simulated scenario, the fictional countries that “prioritized keeping their economies open, undertaking little-to-no NPIs, and downplaying the virus and its potential impacts have experienced much worse outcomes in terms of illness and mortality” than those fictional countries that “promptly adopted aggressive measures to slow virus transmission,” such as “shutting down mass gatherings, imposing social-distancing measures, and implementing mask mandates,” in addition to establishing “large-scale testing and contact-tracing operations.”

This all, of course is to what have learned from accurate, verifiable data from Covid-19.

Gates Foundation, Big-Pharma execs,and the WHO personnel who participated in monkeypox pandemic simulation

Who took part in the NTI’s monkeypox pandemic simulation?

Key participants included:

  • Dr. Ruxandra Draghia-Akli, global head of Johnson & Johnson Global Public Health R&D and Janssen Research & Development.
  • Dr. Chris Elias, president of the global development division of the Bill & Melinda Gates Foundation.
  • Dr. George Gao, director-general of the Chinese Center for Disease Control and Prevention (the Chinese CDC).
  • Dr. Margaret (Peggy) A. Hamburg, interim vice president for global biological policy and programs at NTI, a member of the global health scientific advisory committee for the Gates Foundation and a member of the board of GAVI-The Vaccine Alliance.
  • Sam Nunn, a former U.S. senator who is the founder and co-chair of NTI.
  • Dr. Michael Ryan, executive director of the WHO Health Emergencies Program and a highly visible figure during COVID-19 times.
  • Dr. Petra Wicklandt, head of corporate affairs for Merck.

Do you see any self-interest in this list?

Several of the participants listed above also “participated” in Event 201.

The authors of the report also stand out for their background.

For example, Dr. Jaime M. Yassif, vice president of NTI global biological policy and programs, holds a Ph.D. in biophysics from the University of California-Berkeley and a master’s degree in science and security from the King’s College, London, war studies department.

  • Yassif previously led the initiative on biosecurity and pandemic preparedness at the Open Philanthropy Project, including the management of nearly $40 million in biosecurity grants, the “initiation of new biosecurity work in China and India,” and “establishment of the Global Health Security Index.”

  • She also previously advised the U.S. Department of Defense on science and technology policy and worked on the Global Health Security Agenda at the U.S. Department of Health and Human Services.

Co-author Chris Isaac, program officer for NTI’s Global Biological Policy and Programs team, “has been involved with synthetic biology through the Internationally Genetically Engineered Machines Competition since the start of his scientific career” and “is an alumnus of the Emerging Leaders in Biosecurity Fellowship at the Johns Hopkins Center for Health Security.”

The report is the product of a partnership between NTI, co-founded by Nunn and Ted Turner, and the Munich Security Conference. Both NTI ($3.5 million, for “vaccine development”) and the Munich Security conference ($1.2 million) received funding from the Gates Foundation.

The report itself was funded by the Open Philanthropy project, one of whose main funders is Dustin Moscovitz, co-founder of Facebook along with Mark Zuckerberg.

Open Philanthropy, over the past decade, has provided donations and grants to the following entities and for the following purposes:

  • $166.9 million for “global health.”
  • $90.2 million for “biosecurity and pandemic preparedness.”
  • $18 million for “global catastrophic risks.”
  • $40.2 to Johns Hopkins Center for Health Security.
  • $17.9 to NTI.
  • $2.2 to The Guardian.
  • $1.6 to Rockefeller University.

Johns Hopkins Center for Health Security at center of multiple tabletop exercises

Johns Hopkins — the bastion of innacuate Covid-19 cases and deaths — again? Why would anyone believe them a second time around?

NTI and the Munich Security Conference are not new to “tabletop exercises” — their report highlights previous simulations, including a 2019 report titled “A Spreading Plague,” and a 2020 report titled “Preventing Global Catastrophic Biological Risks.”

Other simulations in the recent past, in addition to Event 201, include:

  • Operation Dark Winter (June 2001, less than three months before the 9/11 attacks and subsequent anthrax scare, “examining the national security, intergovernmental, and information challenges of a biological attack on the American homeland”).
  • Operation Atlantic Storm (January 2005, “designed to mimic a summit of transatlantic leaders forced to respond to a bioterrorist attack”).
  • The Clade X exercise (May 2018, “to illustrate high-level strategic decisions and policies that the United States and the world will need to pursue in order to prevent a pandemic or diminish its consequences should prevention fail”). Yassif helped develop the Clade X exercise.

The common denominator among all of these simulations? The Johns Hopkins Center for Health Security, which published a document titled “The SPARS Pandemic 2025-2028,” comprising “a futuristic scenario that illustrates communication dilemmas concerning medical countermeasures (MCMs) that could plausibly emerge in the not-so-distant future.”

Predictions for the future don’t end there, however. For instance, in September 2017, NTI and the WEF organized a roundtable discussion on the current state of biological risks presented by technology advancement in light of the Fourth Industrial Revolution.

And in January 2020, NTI and the WEF again joined forces, issuing a report titled “Biosecurity Innovation and Risk Reduction: A Global Framework for Accessible, Safe and Secure DNA Synthesis.”

According to that report:

“Rapid advancements in commercially available DNA synthesis technologies — used for example to artificially create gene sequences for clinical diagnosis and treatment — pose growing risks, with the potential to cause a catastrophic biological security threat if accidentally or deliberately misused.”

Merck, whose head of corporate affairs participated in the monkeypox simulation, was the subject of an FBI and CDC investigation in November 2021 regarding 15 suspicious vials labeled “smallpox” at a Merck facility in Philadelphia.

Bill Gates no stranger to predicting the future

Bill Gates has himself been remarkably prescient with his predictions of future events. Here are some of Gates’ predictions:

  • In a November 2015 TED talk, he stated “[i]f anything kills over 10 million people in the next few decades, it’s most likely to be a highly infectious virus rather than a war. Not missiles, but microbes.”
  • In a 2017 speech at that year’s Munich Security Conference, he said “the next epidemic could originate on the computer screen of a terrorist intent on using genetic engineering to create a synthetic version of the smallpox virus,” arguing in favor of the merger of “health security” and “international security.”
  • In May 2021, Gates said “[s]omebody who wants to cause damage could engineer a virus so that the cost, the chance of running into this is more than that of naturally-caused epidemics ”
  • In November 2021, Gates publicly pondered, “[y]ou say, OK, what if a bioterrorist brought smallpox to 10 airports? You know, how would the world respond to that? There’s naturally-caused epidemics and bioterrorism-caused epidemics that could even be way worse than what we experienced today.”
  • In February 2022, Gates warned that the next pandemic “… won’t necessarily be a coronavirus or even the flu. It is likely to be a respiratory virus. Because, with all the human travel we have now, that’s the one that can spread in such a rapid way,” emphasizing the significance of providing sufficient funds to the private sector and academia to build better vaccines, therapeutics and diagnostics.
  • Earlier this month, Gates called for the development of a so-called “Global Epidemic Response and Mobilization” (GERM) initiative, stating that present WHO funding was “not at all serious about pandemics” and that $1 billion a year would be needed to operate this initiative.
  • Also this month, the Bill & Melinda Gates Foundation announced “a new financial commitment of up to US $125 million to help end the acute phase of the COVID-19 pandemic and prepare for future pandemics,” with much of the money going toward “strengthening health systems in low-income countries, enhancing integrated disease monitoring, expanding access to pandemic tools, and helping countries manage COVID-19 alongside other pressing health needs.”
  • In his new book, “How to Prevent the Next Pandemic,” Gates argues that, despite COVID fatigue, the world must focus on preparing for future pandemics, regardless of whether a disease is circulating.

Now, how do we best usher the self-serving Bill Gates off the World Stage?

May 18, 2022: Bavarian Nordic to Manufacture First Freeze-Dried Doses of Smallpox Vaccine [also for the protection against Monkeypox]

. . . Upon Exercise of Contract Option by the U.S. Government


  • USD 119 million option exercised for the manufacturing of freeze-dried JYNNEOS® in 2023 and 2024
  • This represents the first set of options with a total value of USD 299 million to convert the existing bulk vaccine, previously purchased by BARDA, to approximately 13 million freeze-dried JYNNEOS doses

COPENHAGEN, Denmark, May 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the first options under the contract to supply a freeze-dried version of JYNNEOS® smallpox vaccine, thus allowing for the first doses of this version to be manufactured and invoiced in 2023 and 2024.

The options have a value of USD 119 million and represent the first options exercised to convert bulk vaccine, which has already been manufactured and invoiced under previous contracts with BARDA, into freeze dried doses of JYNNEOS smallpox vaccine. Additional options on the contract valued at USD 180 million, if exercised support conversion of up to a total of approximately 13 million freeze dried doses of JYNNEOS smallpox vaccine that are expected to be manufactured in 2024 and 2025. The majority of the bulk vaccine for these doses has already been manufactured and invoiced.

The transfer of the freeze-drying process to our new fill and finish plant in Kvistgaard was initiated last year and following an FDA inspection in 2022 will lead to commercial manufacturing in 2023. A supplement to the existing liquid frozen JYNNEOS BLA will be made comprising the Phase 3 data, which has already been completed and reported, together with the manufacturing data to support the approval of the freeze-dried version of JYNNEOS in 2024. In parallel to these activities, we will, with the award of this first option, begin to manufacture and invoice freeze-dried JYNNEOS doses in 2023 and 2024.

Paul Chaplin, President and CEO of Bavarian Nordic said:

“We are pleased to announce the exercise of the first options under our contract with the U.S. government to deliver a freeze-dried version of the smallpox vaccine with an improved shelf-life, which will be manufactured at our new fill and finish facility. This marks a significant milestone in our long-standing partnership with the U.S. government to ensure availability of life-saving vaccines for the entire population.”

The contents of this announcement do not affect the Company’s expectations for the financial results for 2022.

This project has been supported with US federal funds from the

  1. Department of Health and Human Services;
  2. Office of the Assistant Secretary for Preparedness and Response;
  3. Biomedical Advanced Research and Development Authority,

. . . all under Contract No. HHSO100201700019C.

About Bavarian Nordic smallpox vaccine contracts with the U.S. government

Since 2003, Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine to ensure all populations can be protected from smallpox, including people with weakened immune systems who are at high risk of adverse reactions to traditional smallpox vaccines, which are based on replicating vaccinia virus strains. To date, the Company has supplied nearly 30 million doses of the liquid-frozen version to HHS, with the vast majority being delivered for emergency use before approval of the vaccine by the FDA in 2019.

Since 2009, BARDA has supported the development of a freeze-dried version of the vaccine with longer shelf-life to replace the stockpile and in 2017 awarded the Company a ten-year contract valued at USD 539 million for supply of freeze-dried vaccines. Part of this contract (USD 37 million) has funded the Phase 3 study. Also, under this contract Bavarian Nordic has produced bulk vaccine worth of USD 253 million which will add to the existing stock of bulk manufactured under previous orders, collectively resulting in approximately 13 million doses for future delivery. The majority of the contract (USD 299 million), however, will be realized upon supply of the freeze-dried doses, which will be manufactured at the Company’s the new fill-finish facility.

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox.

The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis.

Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit


  • Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
  • US: Graham Morrell, Paddock Circle Advisors,, Tel: +1 781 686 9600
  • Company Announcement no. 17 / 2022
  • Published on May 18, 2022